Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II combination chemoimmunotherapy for splenic marginal zone lymphoma
2005-000693-45Phase 2Completed
- Sponsor
- Gruppo Italiano Studio Linfomi
- Start
- Apr 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, cyclophosphamide, vincristine, doxorubicin and prednisone in splenic marginal zone lymphoma (SMZL), sponsored by Gruppo Italiano Studio Linfomi. Started Apr 2007; status: completed.
02
Drugs
rituximabcyclophosphamidevincristinedoxorubicinprednisone
03
Conditions
splenic marginal zone lymphoma (SMZL)
Beyond the preview
Go deeper on 2005-000693-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000693-45.